CA1070630A - Dihydromocimycin from streptomyces ramocissimus - Google Patents
Dihydromocimycin from streptomyces ramocissimusInfo
- Publication number
- CA1070630A CA1070630A CA252,534A CA252534A CA1070630A CA 1070630 A CA1070630 A CA 1070630A CA 252534 A CA252534 A CA 252534A CA 1070630 A CA1070630 A CA 1070630A
- Authority
- CA
- Canada
- Prior art keywords
- dihydromocimycin
- mocimycin
- salt
- acceptable salt
- prepared according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/465—Streptomyces
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Molecular Biology (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
A new antibiotic (now called dihydromocimycin) being a yellow, salt-forming weak acid and its non-toxic, pharmaceutically acceptable salts produced by the microorganism Streptomyces ramocissimus or suitable mutants thereof. The antibiotic has antibacterial properties and has been found to be effective against Treponema dysentery, one of the most common swine diseases. Dihydromocimycin may also be converted into mocimycin, which is an antibiotic which possesses interesting growth-promoting properties when added to animal feed, by a dehydrogenation agent. The dehydrogenation may be carried out with selenium dioxide, preferably in the presence of an organic solvent.
A new antibiotic (now called dihydromocimycin) being a yellow, salt-forming weak acid and its non-toxic, pharmaceutically acceptable salts produced by the microorganism Streptomyces ramocissimus or suitable mutants thereof. The antibiotic has antibacterial properties and has been found to be effective against Treponema dysentery, one of the most common swine diseases. Dihydromocimycin may also be converted into mocimycin, which is an antibiotic which possesses interesting growth-promoting properties when added to animal feed, by a dehydrogenation agent. The dehydrogenation may be carried out with selenium dioxide, preferably in the presence of an organic solvent.
Description
- ~o7~630 This invention relates to a new antibiotic designated dihydromocimycin, a process for its production and compositions containing it. The antibiotic is especially useful against the pigs' disease called Treponema dysentery, Vibrio Doyle, etc.
The invention further relates to a process for using dihydromo-cimycin as a starting material for the production of mocimycin.
Dihydromocimycin has the following structural formula OH
Dihydromocimycin is produced by fermenting Streptomyces ramocissimus, or suitable mutants thereof and is formed in addition to mocimycin. Streptomyces ramocissimus is a microorganism described in British Specification No. 1325200, the microorganism is deposited with the culture collection of Centraal Bureau voor Schimmelcultures at Baarn, The Netherlands, where it obtained the number CBS 190.69 and is available to the public.
In British Specification No. 1325200 a process is described and claimed for the production of mocimycin (then called MYC 8003) by the above indicated microorganism. The structure of mocimycin is indicated by Vos and Verwiel in Tetrahedron Letters 52 (1973) pp. 5173-5176. It has now been discovered that Streptomyces ramocissimus, or suitable mutants thereof, produce dihydromocimycin in addition to mocimycin.
Dihydromocimycin is a pale yellow solid substance, weakly acid and further characterized by the following physico-chemical properties:
~r " ~. ' '' ~ ' ' ~
o7063~) Solubility:
The solubility of the compound is good in chloroform, methyl isobutyl ketone, ethyl acetate, butyl acetate, acetone, dioxane, methanol, ethanol, tetrahydrofuran, and in weakly alkaline aqueous solutions. The solubility is moderate in carbon tetrachloride and benzene, and the compound is insoluble in diethyl ether, water, weakly acid aqueous solutions, cyclo-i hexane and petroleum ether.
Optical rotation .
[~]D = -85 (1% methanolic solution).
Melting point:
The compound does not melt, but decomposition starts at 123 C.
Elementary analysis:
The following values were found:
Found:Calculated for C43H62N212 2 C: 61.8% 61.8%
H: 7.5% 8.0~
N: 3.4% 3.3%
O: 27.2% (by difference) 26.8%
` Ultra-violet spectrum:
The ultra-violet spectrum of dihydromocimycin in a 1:1 mixture of water and methanol at various pH values is shown in Figure 1 of the attached drawings. The concentration of the solutions measured was 18.3 ~g/ml. The ultra-violet spectrum ; is dependent on the pH. The following maxima were found (the molecular extinctions are indicated between brackets):
methanol - water: 233.5 nm (E = 63,000); 267 nm ( = 23,000);
291 nm (E = 19,000) and 333 nm (E = 18,000); curve 1;
methanol - 0.5N NaOH: 235 nm (E = 62,000); 277 nm (E = 25,000) and 308 nm (E = 29,000); curve 2;
.` ' ' ' methanol - 0.5N HCl: 233.5 nm (~ = 65,000); 268 nm (~ = 25,000) and 338 nm (~ = 14,000);
curve 3.
Infra-red spectrum:
The I.R. spectrum of dihydromocimycin in chloroform and in potassium bromide is shown in Figures 2 and 3, respectively. The following principal absorptions were found:
chloroform (v in cm 1): +3445 (sh); 3430; 2979; 2941; 2886;
1662-1653; 1458; 1100; 1080; 1040; 998; 944; 893; 870 and 840;
potassium bromide (v in cm 1): +3400-3320; 2972; 2935; 2880;
1650; 1535; 1455; 1099; 1040; 990; 943; 860; 840 and 790.
PMR spectrum:
The PMR spectrum of dihydromocimycin dissolved in deutero-chloroform, using tetramethylsilane as the internal reference, is shown in Figure 4 (60 Mc).
Thin layer chromatography:
Thin layer chromatograms of dihydromocimycin were made on Kieselgel F 254 plates (Merck, ready-for-use plates), and -after drying the spots were detected by fluorescence extinction, ; 20 or by carbonization after spraying with a diethyl ether-sulphuric acid mixture. Investigations showed that the spot ascribed to dihydromocimycin, even the purest preparations, was always accompanied by a small additional spot. The appearance of the two spots is due to a tautomeric equilibrium, as can be shown by a two-dimentional chromatogram.
The following Rf-values were found for dihydromocimycin in various eluents (the Rf-value for the additional spot is indicated between brackets):
50:45:5 mixture of methyl isobutyl ketone, acetone and water:
0.44 (about 0.44);
70:20:10:0.5 mixture of ethyl acetate, methanol, water and 25%
ammonia:
0.29 (0.36);
65:40:9 mixture of benzene, 100~ ethanol and 33~ ammonia:
0.16 (0.22) 60;42:10 mixture of chloroform, 96% ethanol and 25% ammonia:
0.4.
The structural formula of dihydromocimycin is confirmed on the following grounds: The PMR spectra (220 Mc) of mocimycin (cf. Tetrahedron Letters 52 (1973) pp. 5173-5176 for its structural formula) and dihydromocimycin showed that both compounds are similar, except that two doublets at ~ 5.9 and 7.3 ppm (tetramethylsilane was used as the reference), which occurred in the spectrum of mocimycin, did not occur in the spectrum of dihydromocimycin. Those signals are caused by the protons of the 5th and 6th carbon atoms of the pyridone nucleus.
However, two triplets appeared in the spectrum of dihydromocimycin at ~ 2.5 and 3.4 ppm. This is an indication that the bond between the 5th and 6th carbon atoms in the pyridone nucleus of dihydromocimycin is saturated. This interpretation was confirmed by an ozonisation of an aqueous solution of dihydromocimycin at pH 12 during 5 minutes at 0C. After reduction of the reaction mixture obtained with hydrogen catalyzed by PtO2 and after hydrolysis with concentrated hydrochloric acid, ~-alanine was detected, indicating that the bond between the 5th and 6th carbon atoms of the pyridone nucleus of dihydromocimycin is saturated.
Many properties of dihydromocimycin are similar to those of mocimycin. However, there is one important difference:
a low concentration of mocimycin added to the feed of animals being fattened, such as chickens or pigs, improves the growth and the feed-conversion markedly. Dihydromocimycin, on the contrary, does not show any improvement of the growth or feed-conversion of those animals, which is unexpected, since in vitro `` 1070630 it shows activity against the same microorganisms; in many cases it shows even a better activity than mocimycin. A comparison of the antimicro~ial activities of the two antibiotics is indicated in the following table:
Agar dilution tests , _ : ' Organism tested Minimum inhibitory concentration (~g./ml.) in anaerobic culture . , mocimycindihydromocimycin , Staphylococcus aureus A 2000 >100 >100 Staphylococcus aureus A 2001 >100 >100 Diplococcus pneumoniae L54 1.5 <0.75 Salmonella typhimurium R172 >100 >100 Escherichia coli U20>100 100 Listeria monocytogenes A2130 6 1.5 Listeria monocytogenes A2131 6 6 ~F~ monocytogenes A2132 6 6 Clostridium perfringens A738 >100 >100 Clostridium septicum A2152 10 10 Streptococcus zooepidemicus R-Streptococcen A2148 6 3 Brucella suis (smooth) A2126 0.75 0.4 Pasteurella haemolytica A2136 3 1.5 Treponema spec. A227530 10 Li~uid dilution tests ~
. .... _ .. _ __ .. _.. _ _~__.. A. A ._ Organism tested Minimum inhibitory concentra-tion (~g./ml.) mocimycin dihydromocimycin Bacillus subtilis ATCC 6633 100 50 Bacillus subtilis ATCC 6051 100 50 Bacillus subtilis 6346 D167 1.2 0.9 ; Bacillus subtilis 220 D178 75 75 Bacillus subtilis TH 10100 50 Bacillus cereus D166 0.6 0.6 Bacillus cereus D261 0.9 0.6 Bacillus cereus D220 1.2 0.9 Bacillus cereus B569 2.5 1.2 Bacillus cereus TH 1 1.8 1.2 Bacillus thuringiensis Wll 1.2 0.9 Bacillus mesenterium D169 100 50 Bacillus cereus var. mycoides 1.2 0.45 Stre~tococcus haemolyticus A266 0.45 0.45 Streptococcus haemolYticus A2182 0.25 0.12 Mycoplasma ~ 1 0.3 Steptomyces viridochromogenes 2.5 0.9 . , .
. , Streptomyces ramocissimus, under suitable conditions, does produce dihydromocimycin in addition to mocimycin, and therefore, according to a feature of the invention, dihydromocimycin is produced by the process which comprises aerobically cultivating the microorganism Streptomyces ramocissimus (CBS 190.69), or a dihydromocimycin-producingmutant thereof, in an aqueous nutrient medium containing assimilable sources of carbon, nitrogen and inorganic substances, and separating the dihydromocimycin formed during the cultivation. Fermentation of the microorganism may be carried out with the liquid media containing the usual carbon, nitrogen, phosphorus, calcium, iron, sulphur, magnesium, potassium, vitamin and trace-element sources, such as media containing beet molasses, malt paste, peanut flour, ~-lactose, potato starch, corn steep and yeast extract. The temperature of the fermentation medium should be between 20 and 40C, preferably between 26 and 34C, and the pEI between 5 and 9, preferably between 6.5 and 8.
It will be appreciated that the aforesaid process is similar to that for the production of mocimycin, and it has been found that dihydromocimycin is formed under suitable conditions -in addition to mocimycin in the fermentation of Streptomyces ramocissimus, or its mocimycin- (and dihydromocimycin-) producing mutants.
To obtain a greater yield of dihydromocimycin relative to that of mocimycin, it has unexpectedly been found that this is achieved by increasing the oxygen pressure in the culture - medium.
From the structure of dihydromocimycin it would be expected that a higher oxygen pressure in the culture medium would decrease the production of dihydromocimycin with respect to that of mocimycin. However, dihydromocimycin has been found to be produced more abundantly then mocimycin by better aeration of the culture liquid, which may be achieved by techniques known per se, such as a higher aeration rate (volume of air per volume of culture medium per unit of time), a higher agitation rate of the culture medium in the fermenter. Suitable aeration rates of the culture medium, e.g. of about 2 litres, are 1 litre to 3 litres of air (preferably 1.5-2.5 litres) per minute. A
further improvement of the yield of dihydromocimycin is obtained by adding low concentrations of certain metal ions, such as the ions of iron, cobalt and nickel, to the culture medium.
The separation of dihydromocimycin from the culture medium is partially similar to the separation of mocimycin. In the last step, wherein the precipitation of the compounds is from an organic solvent, use is made of a difference in solubilities of mocimycin and dihydromocimycin. Mocimycin is precipitated first after passage of gaseous ammonia through the solution, and the separation may be carried out by introducing ammonia through the solution until substantially all mocimycin is precipitated, and substantially all dihydromocimycin is left in the solution.
This may be controlled, e.g. by thin-layer chromatographic tests.
After separating, e.g. filtering off, the mocimycin precipitate from the solution, the passage of ammonia is continued until substantially all dihydromocimycin is precipitated so that it can be separated, e.g. filtered off. The ammonia is, for example, passed through the solution at a speed of about 150 litres per litre of solution per hour during about 1 to about 4 minutes (i.e. about 2.5 to about 10 litres of gaseous ammonia per litre of solution) at a temperature between about -12C to about +15C, preferably between -5C and +8C. Upon continued passage of gaseous ammonia through the solution, the hydrogen ion concentration decreases sufficiently to make dihydromocimycin insoluble when the ammonia is passed with the above indicated speed during the 10 to about 15 minutes (corresponding to about 25 to about 40 litres of gaseous ammonia) under the same circumstances. In addition to ammonia, generally all alkaline compounds may be used for the separation of mocimycin and dihydromocimycin, e.g.
sodium methoxide and triethylamine.
The crude dihydromocimycin thus separated from the culture medium is further purified from mocimycin by dissolving the precipitate in a highly diluted ammoniacal solution (pH 9) and extracting this solution with a solvent such as chloroform or methylene chloride. Mocimycin is poorly soluble in such a solvent, and by pouring the extract obtained into an excess of an apolar solvent (e.g. petroleum ether, cyclohexane or pentane3 a precipitate is formed of dihydromocimycin containing less than 5~ of mocimycin.
Highly purified dihydromocimycin can be obtained by passing the product obtained in the way just described over a SEPHADEX (Trade Mark) LH 20 column using the difference in adsorption of mocimycin and dihydromocimycin. The SEPHADEX is suspended in 100% methanol and poured carefully into the column.
After displacement of the methanol with chloroform, the above-mentioned dihydromocimycin precipitate is brought into the column. The eluent used is chloroform. After some time dihydromocimycin is obtained first, followed by mocimycin. Both compounds can be detected in the eluate since they show absorption in the ultra-violet spectrum at 350 nm. The pure compounds may be recovered from the chloroform by precipitation with an apolar solvent such as cyclohexane or pentane.
Confirmation of the identity of the compounds can be obtained by thin layer chromatography. Use is made of Kieselgel F 254 plates, size 20x5 cm (Merck). The eluent is a 60:42:10 mixture of chloroform, ethanol and 25~ ammonia, respectively. Elution time 2 hours. Mocimycin shows an Rf value of 0.3 (main tautomer) and dihydromocimycin shows an Rf value of :`1070630 0.4 (main tautomer).
In an early stage of investigation it was presumed that mocimycin, having a similar anti-microbial spectrum to that of tylosin ~Merck Index, 8th Ed. page 1089), might be effective against Treponema hyodysenteriae causing Treponema dysentery or Vibrio Doyle, one of the most common swine diseases.
Experiments at that time showed that mocimycin was active against this disease, but not more so than tylosin. For that reason no :
further investigations were carried out.
lO As indicated hereinbefore, dihydromocimycin was found to be more active than mocimycin against many microorganisms, and consequently an investigation with this substance was made against the microorganism causing Treponema dysentery. From the experiments it appeared that dihydromocimycin possesses a markedly higher activity against the microorganisms than tylosin and, in addition, was active against tylosin-resistant strains. Thus, dihydromocimycin may be regarded as being superior to tylosin (and also to mocimycin) in the treatment of Treponema dysentery.
According to another feature of the invention there are provided pig feedstuffs supplemented by a significant proportion of dihydromocimycin or a slat, e.g. sodium salt, thereof. The antibiotic or its alkali metal or ammonium or amine salt thereof may also be dispersed in, or mixed with, any suitable inert, physiologically innocuous carrier or diluent, which is orally administrable to a pig, non-reactive with the antibiotic -and not harmful to the pig on oral administration. Effective amounts of dihydromocimycin incorporated in a pig feedstuff for the prevention or treatment of Treponema dysentery are about lO
to about 200 ppm, preferably 20 to 40 ppm, of dihydromocimycin, based on the weight of the feed.
Dihydromocimycin obtained by the procedure hereinbefore described is a fine, easily dusting powder. This could lead to difficulties in the mixing procedure with the feed and, therefore, a premix is preferably made with one or more of the components of the pig feed containing, for example, a 9 to 99-fold amount of the dihydromocimycin. Suitable components for preparing the premix are, for example, corn flour, potato flour and soya flour. Experiments have shown that dihydromocimycin ; has a good stability against pelletising ~granulating under high pressure at high temperatures, using steam).
The premix can be added to the feed as a prophylactic means or as a means for the treatment of pigs only lightly attacked with Treponema dysentery.
When pigs are attacked so heavily with Treponema dysentery that their appetite is lost, or that the sick pigs are pushed away from the feeding trough by healthy pigs, dihydromocimycin is preferably administered through the drinking water, preferably in the presence of a flavouring corrigent.
For that purpose dihydromocimycin is used in a water-soluble form, such as a salt, e.g. a potassium, sodium or amine salt.
Pigs badly attacked with dysentery may be treated by injection of dihydromocimycin or a water-soluble salt thereof, suspended or dissolved in a usual injection liquid, for example, saline, propylene glycol, glycerol-water mixtures, etc.
P,~ Mocimycin shows advantageous growth-promoting properties when fed to live-stock including chickens and other fowl, but dihydromocimycin does not show the aforesaid properties. In addition, therefore, attempts have been made to convert dihydromocimycin into the, for this application, more useful mocimycin.
It has thus been found that dehydrogenation of dihydromocimycin is possible with a special dehydrogenating substance and procedure. Quinones, e.g. 2,3-dicyano-5,6-dichloro-1,4-quinone, p-chloranil and o-chloranil, are not satisfactory ~...
:' -~070630 for the dehydrogenation of dihydromocimycin as other products -~
are formed. Halogenation with cupric bromide, bromine, iodine or N-bromosuccinimide, followed by dehydrohalogenation, did not give the desired result either, even in the presence of catalysts such as benzoyl peroxide and a,~-azo-isobutyronitrile. Attempts to dehydrogenate dihydromocimycin catalytically involve too high temperatures which would lead to decomposition of dihydromocimycin.
Only one dehydrogenation agent, selenium dioxide, has been found to be useful for the dehydrogenation of dihydromocimycin.
Therefore the present invention further relates to a process for the dehydrogenation of dihydromocimycin into mocimycin, which comprises reacting dihydromocimycin with selenium dioxide. This process may advantageously be applied to mixtures of dihydromocimycin and mocimycin as obtained, for example, by the recovery of mocimycin from fermentation liquids in which it is formed.
The dehydrogenation of dihydromocimycin with selenium dioxide may be carried out at ambient temperature, but is preferably carried out at elevated temperatures, e.g. from about 65 to about 110C, preferably from 80 to 95C. The reaction time is from about 10 hours to about 20 minutes in the temperature range of about 65 to about 110C, and is preferably from about 3 hours to about 1 hour in the preferred temperature range. At ambient temperatures the reaction takes about a week.
The reaction is preferably carried out in a solvent medium. Suitable solvents are, for example, hexamethylphosphor-~ triamide (HMPT), dimethyl sulphoxide (DMSO), t-butanol, t-amyl - alcohol, sec-butanol, hexylene glycol, n-butanol, isopropanol, methylcellosolve, dimethylformamide, water, phenylmethylcarbinol and propanol, and mixtures of two or more of those solvents.
Preferred solvents are HMPT, DMSO and t-butanol. The most preferred solvent is HMPT.
:`
-- ~070630 Based on dihydromc)cimycin, a stoichiometric amount or an excess of selenium dioxide is preferred to carry out the dehydrogenation reaction.
Since isolation of both products together from the fermentation liquid is a simple procedure, whereas the separation of dihydromocimycin and mocimycin is much more difficult, the discovery that dihydromocimycin may be converted by chemical means into - for the growth promotion valuable properties -mocimycin, even in a mixture of both compounds, leaving the latter compound substantially unaffected by the process, is very important. Therefore, isolation of the compounds is not necessary for the dehydrogenation of dihydromocimycin in mixtures containing dihydromocimycin and mocimycin.
The invention is illustrated by the following examples.
Preparation of dihydromocimycin The microorganism Streptomyces ramocissimus (CBS 190.69) was fermented in 2,000 litres of a medium containing 20 g of malt paste, 10 g of yeast extract and 5 g of corn steep solids per litre at a pH of about 7 with agitation and aeration. After fermentation the culture medium was mixed with about 2~ of dicalite (an expanded perlite, an aluminium silicate containing potassium, sodium and trace elements) as filter aid, and the mixture was filtered. The filtrate was acidified with 8N
sulphuric acid to pH 6.0 and extracted twice with 1/5th of its volume of methyl isobutyl ketone (MIBK) and emulsions formed were broken with*Hyflo Supercel filter aid (a diatomaceous earth). The organic liquids were mixed and concentrated to about 1 litre by evaporation under reduced pressure and evaporation with a rotary evaporator. From the concentrate formed a crude product was obtained by adding it to 5 times its own volume of petroleum ether (b.p. 40 to 60C) and the precipitate formed *Trade Mark D
1(~7~630 was filtered off with a glass filter (G 3). The precipitate was washed with fresh petroleum ether and dried to obtain a yellow coloured powder containing mocimycin and dihydromocimycin.
A purified form of dihydromocimycin containing not more than 5% of mocimycin was obtained as follows: Gaseous ammonia was passed through the concentrate at a rate of 150 litres per litre of concentrate per hour for 1 minute at a temperature of 2C. A precipitate was formed which contained mocimycin. The precipitate was filtered off and the filtrate was treated once more with gaseous ammonia for 10 to 15 minutes.
The precipitate now formed was filtered off and dissolved in dilute ammonia (pH 9.0). This solution was extracted with an equal volume of methylene chloride and the extract was poured out into 3 to 5 times its own volume of cyclohexane. The precipitate obtained was filtered off, dried and powdered.
The sodium salt of dihydromocimycin was obtained by dissolving dihydromocimycin in water with addition of 0.1N
sodium hydroxide to pH 9 until a saturated solution was obtained.
The solution was filtered and evaporated azeotropically with addition of butanol (in vacuo at about 45C), and the butanolic residue was collected in a small amount of anhydrous butanol.
Petroleum ether was added dropwise to the stirred solution until all the salt was precipitated. The precipitate was filtered off, washed and dried to give the sodium salt of dihydromocimycin. Other salts of dihydromocimycin were prepared in a similar manner.
Preparation of dihydromocimycin in higher yields To obtain a higher yield of dihydromocimycin, a lyophilised culture of Streptomyces ramocissimus (CBS 190.69), or a well sporulated agar culture of the said microorganism, was used for inoculating the contents of a 500 ml erlenmeyer flask containing 100 ml of a sterilised medium of the following ^` 10~0630 composition: 20 g of malt paste, 10 g of yeast extract and 5 g of corn steep solids per litre of tap water, pH 7Ø
After incubation on a rotating shaking device (300 rpm, stroke 2.5 cm) at 30C for three days, the culture obtained was used for inoculating small fermenters containing 2000 ml of the above-mentioned medium to which 20 mg of CoC12.6H20 per litre was added. This growth phase, also effected at 30C, was carried out under conditions of very good aeration in order to stimulate production of dihydromocimycin. For that purpose, more than 2 litres of sterile air were blown through the culture medium per minute, and the culture medium was stirred at a speed up to 1000 rpm. The production of dihydromocimycin started after a fermentation time of about 12 hours and was maximal after about 120 hours. Fermentation on a larger scale was possible by using a 48 hours old culture medium obtained in small fermenters as inoculum for large fermenters.
The dihydromocimycin so produced was recovered from the culture medium as follows: After addition of 2% of diatomaceous earth as a filter aid, the culture was filtered and the filtrate was acidified with 8N sulphuric acid to a pH of 5 to 6 and was extracted twice with 1/5th of its volume of MIBK. If an emulsion formed, it was broken by filtration of the mixture after addition of some diatomaceous earth. The organic layers were collected and concentrated in vacuo to about l/lOth of the original culture volume. Gaseous ammonia was passed through the concentrate at a rate of 150 litres per litre of concentrate per hour for 1 minute. A precipitate was formed which was filtered off. The filtrate was treated once more with gaseous ammonia for 10 to 15 minutes. The precipitate then obtained was dissolved in dilute ammonia (pH 9.0) and purified dihydromocimycin (containing not more than 5% of mocimycin) was obtained by extracting the solution in ammonia with an equal -~ 1070630 volume of methylene chloride. The extract was poured into 3 to 5 times its own volume of cyclohexane and the precipitate obtained was filtered off, dried and powdered.
Dihydromocimycin against Treponema dysentery Twenty pigs, three months old, were infected with the microorganism causing Treponema dysentery by administering to them feed mixed with a homogeneous mixture of contents of the intestines and intestinal mucous membranes of two animals suffering from the disease. The infected pigs were divided up into four groups of five animals each and the animals were fed with the feed as a slurry diluted 1:1 with water for 1 week. The total amount of feed per animal was 1.2 kg each day and was given in two portions.
After S days the first symptoms of the disease were observed from the thin faeces and confirmed by a microbiological investigation of the faeces. After a week the animals were treated as follows:
group 1: no antibiotic was added to the feed;
group 2: 100 ppm of tylosin were added to the feed group 3: 25 ppm of dihydromocimycin were added to the feed~
group 4: 50 ppm of dihydromocimycin were added to the feed.
The antibiotic-enriched feed was administered for a week. After that week feed without any antibiotic was given again. Recovery from the infection was observed from the weights of the animals and from inspection of samples of the faeces, macroscopically from their consistencies, and microscopically by means of a specific immuno-fluorescence technique.
During the test one animal of each groups 1, 3 and 4 died.
The results are shown in the following table, wherein the weights indicated are the averages at that time of the still .
~ - 15 -107()630 living animals. The consistency of the faeces is indicated as follows:
+ means thin liquid; + means thick liquid; - means normal.
The results of the immuno-fluorescence technique are indicated quantitatively by indicating the number of Treponemas in the visual field: 5 means very crowded; 4 means many 3 means about 10 Treponemas; 2 means 1 or 2 Treponemas, 1 means more visual fields necessary to find one Treponema and - means negative.
Group 1 ¦ Group 2 ¦ Group 3 ¦ Group 4 Weights in kg just before infection 24.6 24.4 24.2 23.4 after 1 week (1) 23.7 22.2 21.3 21.6 after 2 weeks 20.9 21.4 20.2 21.2 after 3 weeks 19 8 23.2 24.0 23.0 Faeces consistency - .
after 1 week + + + + + + + + + _ + + + + ~ + + + + +
after 2 weeks + + + + + + + + + + + + + + + + ~ + +
after 3 weeks + + + + ~ + + + + _ _ + + _ _ + _ Immunofluorescence . , ; after 1 week 4 4 4 4 5 4 4 3 4 - 5 4 5 5 ~ 5 - 5 3 3 after 2 weeks 4 4 4 - 4 4 4 2 2 - 4 4 3 1 2 - ~ 4 1 after 3 weeks 2 2 2 2 ~ 3 - - 2 - _ _ - 1 _ _ _ _ (1) at which time the administration of the antibiotics is started;
means: an animal died.
From the faeces consistency as well as from immunofluorescence observations it appeared that the animals treated with dihydromocimycin were cured markedly faster than the animals treated with tylosin. When the administered amounts of antibiotics were also taken into account, it can be concluded ~. ~0~;30 that dihydromocimycin is at least 4 times as active as tylosin.
Dihydromocimycin against Treponema dysentery Pigs, from a farm where problems with pigs scour had existed for some time, were treated under the supervision of the local veterinary surgeon and the inspector of the Health Service Station. The pigs were divided into groups and treated for 4 days in the following manner:
group 1: 66 pigs were treated with feed containing 100 ppm of tylosin;
group 2: 34 pigs were treated with feed containing 25 ppm of dihydromocimycin; '}
group 3: 40 pigs were treated with feed containing 50 ppm of dihydromocimycin;
group 4: 40 pigs were treated with feed containing 100 ppm of dihydromocimycin.
Before the treatment all animals lost thin or very thin faeces. Samples thereof were investigated and found to be Treponema-positive, and Salmonella-negative. Sometimes worm eggs were found.
One day after the start of the treatment the faeces of the pigs of group 4 were normal. The animals of group 1 were cured only after 3 to 4 days. The animals of groups 2 and 3 were cured in periods lying between those of groups 1 and 4.
The animals treated with dihydromocimycin appeared to be much more liverly than before the treatment. The animals were not averse to feed containing dihydromocimycin and the general conclusion was that a dosage of 25 ppm of dihydromocimycin was better than a dosage of 100 ppm of tylosin in the curing of Treponema dysentery.
"` 1070630 Dehydrogenation of dihydromocimycin A solution was made of 1 g of dihydromocimycin in 15 ml of HMPT (technical grade, dried over a molecular sieve 3A) and an amount of 139 mg (1.25 mmoles) of selenium dioxide was added.
The mixture was heated on a steam bath for 100 minutes and an additional amount of 139 mg of selenium dioxide was added after 60 minutes. The selenium formed after cooling was separated by filtration through a G4 glass filter and the precipitate was washed with a small amount of methanol. The filtrate was poured into 350 ml of distilled water and the precipitate formed was filtered off and washed with distilled water. The filtrate was stored.
; The precipitate was dissolved in methanol and diluted with MIBK. The solution was evaporated at 40C under reduced pressure until methanol and water were removed. A precipitate was formed which did not contain mocimycin as indicated by a thin-layer chromatographed (TLC) test and it consisted of polar impurities only. The precipitate was filtered off and washed with MIBK. The filtrate was added dropwise to an excess of petroleum ether (b.p. 40 to 60C) and the precipitate formed was filtered off, washed with petroleum ether and dried to obtain 500 mg of product.
The stored filtrate was extracted with MIBK, and the extract was added dropwise to petroleum ether to obtain another 100 mg of product of the same quality so that the total yield was 650 g. A thin layer chromatographic test showed that the final product contained mocimycin with only a trace of dihydromocimycin.
Dehydrogenation of dihydromocim~cin .
This experiment was carried out in duplicate. 2.4 g 1~70630 of a composition containing 22.8% of mocimycin and 35.5% of dihydromocimycin was dissolved in 50 ml of HMPT. An amount of 350 mg of selenium dioxide was added and the mixture was kept at 105C for 45 minutes with stirring. According to a thin layer chromatographic test dihydromocimycin was not present anymore.
The mixture was cooled to room temperature and filtered through a glass filter G 4, removing the black selenium formed and a small amount of unreacted selenium dioxide.
The precipitate was washed with MIBK and to the combined filtrate and MIBK washings 350 ml of water, 10 g of sodium chloride and 5 ml of 4 N hydrogen chloride were added.
This mixture was extracted 3 times with 100 ml of MIBK each.
The combined MIBK extracts were washed with 100 ml of water and the water layer was removed. The MIBK phase was dried over anhydrous magnesium sulphate which eventually was washed with a little MIBK. The MIBK phase was then evaporated in vacuo at a temperature of about 20C until 25 ml were left. The residue was added dropwise to 500 ml of stirred petroleum ether (40 - 60C) and the precipitate formed was filtered off, washed with petroleum ether (40 - 60C) and dried in a vacuum drying oven at room temperature during the night.
In the first experiment the following yield was obtained: 1.64 g of a product containing 41.2% of mocimycin and ~ 2% of dihydromocimycin (as determined by high pressure liquid chromatography).
In the second experiment the yield was 1.79 g of a product containing 41.6% of mocimycin and _ 1% of dihydromocimycin.
Dehydrogenation of dihydromocimycin, influence of solvents In this example several solvents were tested to find ; out which one is preferred for the dehydrogenation of dihydromoci-mycin. In all experiments 50 mg of a technical preparation .. -- 19 --.:
, . . . . . .
containing dihydromocimycin and mocimycin were reacted with 20 mg (0.18 mmole) of selenium dioxide in 3 ml of solvent at a temperature of 80C. At 2, 4 and 7 hours after the start a sample was taken for a thin-layer chromatographic test (if necessary after sample preparation) on a "Kieselgel" 60 disc (Merck) using a 50:45:5 mixture of MIBK, acetone and water as the eluent. Detection was carried out by carbonization after spraying with a sulphuric acid-diethyl ether mixture. A
qualitative picture of the reaction was obtained in this manner.
The results are as follows: Decomposition or no reaction was obtained in propargyl alcohol, diacetone alcohol, nitromethane, propylene carbonate, acetonitrile, pyridine, sulpholane, benzylalcohol, mesityl oxide, ethylene carbonate, N-methyl-2-pyrrolidone, N,N-dimethylacetamide, dioxan, MIBK, butyl acetate, amyl acetate, N-methylacetamide, anisole, diglyme and 1,2-dichloroethane. A poor conversion was obtained in tetramethylurea, a 0.1 M buffer of NaHCO3/Na2CO3 of pH 9.1, n-propanol, phenylmethylcarbinol, water, and dimethylformamide.
A somewhat better conversion was obtained in methylcellosolve, isopropanol, n-butanol, hexylene glycol, sec-butanol and t-amyl alcohol. A moderate conversion was obtained in t-butanol, and dimethyl sulphoxide. The best result was obtained in HMPT.
Dehydrogenation of dihydromocimycin in mixtures of solvents In this Example mixtures of solvents with HMPT as one of the components were tested to find out the preferred mixture for carrying out the dehydrogenation of dihydromocimycin.
In each of the experiments 2.4 g of the preparation as used as the starting material in Example 7 were used. After the reaction (i.e. after all dihydromocimycin was converted according to a TLC test), the reaction mixtures were recovered as follows:
..
1~7C~630 After cooling the reaction mixture was filtered through a G4 glass filter to remove the selenium formed and the filter was washed with a small amount of methanol. The filtrate was poured into an excess of water and was acidified to pH 3 and then extracted three times with 1/4th of its volume of MIBK. A tarry interlayer which was formed was extracted with MIBK again by dissolving it in methanol first and diluting it with MIBK and water thereafter. The combined MIBK extracts were washed three times with l/3rd of its volume of water, and the organic layer was concentrated in vacuo at about 40C. In all cases a precipitate was formed essentially consisting of decomposition products (according to TLC). The.precipitate was filtered and washed with MIBK and the combined MIBK
concentrates were added slowly, with stirring, to an excess of petroleum ether (b.p. 40 to 60C). The precipitate formed was filtered, washed with petroleum ether and dried.. The results of the experiments are shown in the following table:
.
-- 107()630 Amount of Reaction Overall SeO2- Yield Moles solvent temperature reaction addltion (% by SeO2 (C) time in grams weight) added (hrs) and time per of mole of addition mixture after start of reaction HMPT 25 ml 90 2 0.5 start 423:1 H2O 35 ml + 0.5 after 55 min . I .
HMPT 15 ml 90 2 3/4 0.1 start 501.2:1 0.1 M 0.1 after NaHCO3- 20 min Na CO 0.1 after bu~fe~ pH 85 min 9.1 25 ml 0.1 after 130 min .
t-BuOH 84 3 0.1 start 421.5:1 20 ml 0.1 after HMPT 10 ml 25 min 45 min 0.1 after 75 min 0.1 after 120 min ~ 30 t-AmOH 96 0.3S start 71 3.2:1 : 100 ml 0.35 afte HMPT 50 ml 70 min :
: 0.35 after . 110 min I ~
t-AmOH 96 3 0.35 start 55 3.2:1 150 ml 0.35 after 75 min :~:
0.35 after .
. 150 min ; .
t-BuOH 80 2 1.0 start 426:1 100 ml 1.0 after HMPT 50 ml 35 min HMPT 95reaction 0.4 start 791.2:1 150 ml stopped after 1 hr .. . . . .
.
1~70630 The following abbrevations are used:
HMPT = hexamethylphosphortriamide t-BuOH = t-butanol t-AmOH = t-amyl alcohol The table shows that the highest yield (79~) is obtained when pure HMPT is used as the solvent. A high yield is also obtained in a mixture of HMPT and t-amyl alcohol.
' ... .
.
: ` : . .
The invention further relates to a process for using dihydromo-cimycin as a starting material for the production of mocimycin.
Dihydromocimycin has the following structural formula OH
Dihydromocimycin is produced by fermenting Streptomyces ramocissimus, or suitable mutants thereof and is formed in addition to mocimycin. Streptomyces ramocissimus is a microorganism described in British Specification No. 1325200, the microorganism is deposited with the culture collection of Centraal Bureau voor Schimmelcultures at Baarn, The Netherlands, where it obtained the number CBS 190.69 and is available to the public.
In British Specification No. 1325200 a process is described and claimed for the production of mocimycin (then called MYC 8003) by the above indicated microorganism. The structure of mocimycin is indicated by Vos and Verwiel in Tetrahedron Letters 52 (1973) pp. 5173-5176. It has now been discovered that Streptomyces ramocissimus, or suitable mutants thereof, produce dihydromocimycin in addition to mocimycin.
Dihydromocimycin is a pale yellow solid substance, weakly acid and further characterized by the following physico-chemical properties:
~r " ~. ' '' ~ ' ' ~
o7063~) Solubility:
The solubility of the compound is good in chloroform, methyl isobutyl ketone, ethyl acetate, butyl acetate, acetone, dioxane, methanol, ethanol, tetrahydrofuran, and in weakly alkaline aqueous solutions. The solubility is moderate in carbon tetrachloride and benzene, and the compound is insoluble in diethyl ether, water, weakly acid aqueous solutions, cyclo-i hexane and petroleum ether.
Optical rotation .
[~]D = -85 (1% methanolic solution).
Melting point:
The compound does not melt, but decomposition starts at 123 C.
Elementary analysis:
The following values were found:
Found:Calculated for C43H62N212 2 C: 61.8% 61.8%
H: 7.5% 8.0~
N: 3.4% 3.3%
O: 27.2% (by difference) 26.8%
` Ultra-violet spectrum:
The ultra-violet spectrum of dihydromocimycin in a 1:1 mixture of water and methanol at various pH values is shown in Figure 1 of the attached drawings. The concentration of the solutions measured was 18.3 ~g/ml. The ultra-violet spectrum ; is dependent on the pH. The following maxima were found (the molecular extinctions are indicated between brackets):
methanol - water: 233.5 nm (E = 63,000); 267 nm ( = 23,000);
291 nm (E = 19,000) and 333 nm (E = 18,000); curve 1;
methanol - 0.5N NaOH: 235 nm (E = 62,000); 277 nm (E = 25,000) and 308 nm (E = 29,000); curve 2;
.` ' ' ' methanol - 0.5N HCl: 233.5 nm (~ = 65,000); 268 nm (~ = 25,000) and 338 nm (~ = 14,000);
curve 3.
Infra-red spectrum:
The I.R. spectrum of dihydromocimycin in chloroform and in potassium bromide is shown in Figures 2 and 3, respectively. The following principal absorptions were found:
chloroform (v in cm 1): +3445 (sh); 3430; 2979; 2941; 2886;
1662-1653; 1458; 1100; 1080; 1040; 998; 944; 893; 870 and 840;
potassium bromide (v in cm 1): +3400-3320; 2972; 2935; 2880;
1650; 1535; 1455; 1099; 1040; 990; 943; 860; 840 and 790.
PMR spectrum:
The PMR spectrum of dihydromocimycin dissolved in deutero-chloroform, using tetramethylsilane as the internal reference, is shown in Figure 4 (60 Mc).
Thin layer chromatography:
Thin layer chromatograms of dihydromocimycin were made on Kieselgel F 254 plates (Merck, ready-for-use plates), and -after drying the spots were detected by fluorescence extinction, ; 20 or by carbonization after spraying with a diethyl ether-sulphuric acid mixture. Investigations showed that the spot ascribed to dihydromocimycin, even the purest preparations, was always accompanied by a small additional spot. The appearance of the two spots is due to a tautomeric equilibrium, as can be shown by a two-dimentional chromatogram.
The following Rf-values were found for dihydromocimycin in various eluents (the Rf-value for the additional spot is indicated between brackets):
50:45:5 mixture of methyl isobutyl ketone, acetone and water:
0.44 (about 0.44);
70:20:10:0.5 mixture of ethyl acetate, methanol, water and 25%
ammonia:
0.29 (0.36);
65:40:9 mixture of benzene, 100~ ethanol and 33~ ammonia:
0.16 (0.22) 60;42:10 mixture of chloroform, 96% ethanol and 25% ammonia:
0.4.
The structural formula of dihydromocimycin is confirmed on the following grounds: The PMR spectra (220 Mc) of mocimycin (cf. Tetrahedron Letters 52 (1973) pp. 5173-5176 for its structural formula) and dihydromocimycin showed that both compounds are similar, except that two doublets at ~ 5.9 and 7.3 ppm (tetramethylsilane was used as the reference), which occurred in the spectrum of mocimycin, did not occur in the spectrum of dihydromocimycin. Those signals are caused by the protons of the 5th and 6th carbon atoms of the pyridone nucleus.
However, two triplets appeared in the spectrum of dihydromocimycin at ~ 2.5 and 3.4 ppm. This is an indication that the bond between the 5th and 6th carbon atoms in the pyridone nucleus of dihydromocimycin is saturated. This interpretation was confirmed by an ozonisation of an aqueous solution of dihydromocimycin at pH 12 during 5 minutes at 0C. After reduction of the reaction mixture obtained with hydrogen catalyzed by PtO2 and after hydrolysis with concentrated hydrochloric acid, ~-alanine was detected, indicating that the bond between the 5th and 6th carbon atoms of the pyridone nucleus of dihydromocimycin is saturated.
Many properties of dihydromocimycin are similar to those of mocimycin. However, there is one important difference:
a low concentration of mocimycin added to the feed of animals being fattened, such as chickens or pigs, improves the growth and the feed-conversion markedly. Dihydromocimycin, on the contrary, does not show any improvement of the growth or feed-conversion of those animals, which is unexpected, since in vitro `` 1070630 it shows activity against the same microorganisms; in many cases it shows even a better activity than mocimycin. A comparison of the antimicro~ial activities of the two antibiotics is indicated in the following table:
Agar dilution tests , _ : ' Organism tested Minimum inhibitory concentration (~g./ml.) in anaerobic culture . , mocimycindihydromocimycin , Staphylococcus aureus A 2000 >100 >100 Staphylococcus aureus A 2001 >100 >100 Diplococcus pneumoniae L54 1.5 <0.75 Salmonella typhimurium R172 >100 >100 Escherichia coli U20>100 100 Listeria monocytogenes A2130 6 1.5 Listeria monocytogenes A2131 6 6 ~F~ monocytogenes A2132 6 6 Clostridium perfringens A738 >100 >100 Clostridium septicum A2152 10 10 Streptococcus zooepidemicus R-Streptococcen A2148 6 3 Brucella suis (smooth) A2126 0.75 0.4 Pasteurella haemolytica A2136 3 1.5 Treponema spec. A227530 10 Li~uid dilution tests ~
. .... _ .. _ __ .. _.. _ _~__.. A. A ._ Organism tested Minimum inhibitory concentra-tion (~g./ml.) mocimycin dihydromocimycin Bacillus subtilis ATCC 6633 100 50 Bacillus subtilis ATCC 6051 100 50 Bacillus subtilis 6346 D167 1.2 0.9 ; Bacillus subtilis 220 D178 75 75 Bacillus subtilis TH 10100 50 Bacillus cereus D166 0.6 0.6 Bacillus cereus D261 0.9 0.6 Bacillus cereus D220 1.2 0.9 Bacillus cereus B569 2.5 1.2 Bacillus cereus TH 1 1.8 1.2 Bacillus thuringiensis Wll 1.2 0.9 Bacillus mesenterium D169 100 50 Bacillus cereus var. mycoides 1.2 0.45 Stre~tococcus haemolyticus A266 0.45 0.45 Streptococcus haemolYticus A2182 0.25 0.12 Mycoplasma ~ 1 0.3 Steptomyces viridochromogenes 2.5 0.9 . , .
. , Streptomyces ramocissimus, under suitable conditions, does produce dihydromocimycin in addition to mocimycin, and therefore, according to a feature of the invention, dihydromocimycin is produced by the process which comprises aerobically cultivating the microorganism Streptomyces ramocissimus (CBS 190.69), or a dihydromocimycin-producingmutant thereof, in an aqueous nutrient medium containing assimilable sources of carbon, nitrogen and inorganic substances, and separating the dihydromocimycin formed during the cultivation. Fermentation of the microorganism may be carried out with the liquid media containing the usual carbon, nitrogen, phosphorus, calcium, iron, sulphur, magnesium, potassium, vitamin and trace-element sources, such as media containing beet molasses, malt paste, peanut flour, ~-lactose, potato starch, corn steep and yeast extract. The temperature of the fermentation medium should be between 20 and 40C, preferably between 26 and 34C, and the pEI between 5 and 9, preferably between 6.5 and 8.
It will be appreciated that the aforesaid process is similar to that for the production of mocimycin, and it has been found that dihydromocimycin is formed under suitable conditions -in addition to mocimycin in the fermentation of Streptomyces ramocissimus, or its mocimycin- (and dihydromocimycin-) producing mutants.
To obtain a greater yield of dihydromocimycin relative to that of mocimycin, it has unexpectedly been found that this is achieved by increasing the oxygen pressure in the culture - medium.
From the structure of dihydromocimycin it would be expected that a higher oxygen pressure in the culture medium would decrease the production of dihydromocimycin with respect to that of mocimycin. However, dihydromocimycin has been found to be produced more abundantly then mocimycin by better aeration of the culture liquid, which may be achieved by techniques known per se, such as a higher aeration rate (volume of air per volume of culture medium per unit of time), a higher agitation rate of the culture medium in the fermenter. Suitable aeration rates of the culture medium, e.g. of about 2 litres, are 1 litre to 3 litres of air (preferably 1.5-2.5 litres) per minute. A
further improvement of the yield of dihydromocimycin is obtained by adding low concentrations of certain metal ions, such as the ions of iron, cobalt and nickel, to the culture medium.
The separation of dihydromocimycin from the culture medium is partially similar to the separation of mocimycin. In the last step, wherein the precipitation of the compounds is from an organic solvent, use is made of a difference in solubilities of mocimycin and dihydromocimycin. Mocimycin is precipitated first after passage of gaseous ammonia through the solution, and the separation may be carried out by introducing ammonia through the solution until substantially all mocimycin is precipitated, and substantially all dihydromocimycin is left in the solution.
This may be controlled, e.g. by thin-layer chromatographic tests.
After separating, e.g. filtering off, the mocimycin precipitate from the solution, the passage of ammonia is continued until substantially all dihydromocimycin is precipitated so that it can be separated, e.g. filtered off. The ammonia is, for example, passed through the solution at a speed of about 150 litres per litre of solution per hour during about 1 to about 4 minutes (i.e. about 2.5 to about 10 litres of gaseous ammonia per litre of solution) at a temperature between about -12C to about +15C, preferably between -5C and +8C. Upon continued passage of gaseous ammonia through the solution, the hydrogen ion concentration decreases sufficiently to make dihydromocimycin insoluble when the ammonia is passed with the above indicated speed during the 10 to about 15 minutes (corresponding to about 25 to about 40 litres of gaseous ammonia) under the same circumstances. In addition to ammonia, generally all alkaline compounds may be used for the separation of mocimycin and dihydromocimycin, e.g.
sodium methoxide and triethylamine.
The crude dihydromocimycin thus separated from the culture medium is further purified from mocimycin by dissolving the precipitate in a highly diluted ammoniacal solution (pH 9) and extracting this solution with a solvent such as chloroform or methylene chloride. Mocimycin is poorly soluble in such a solvent, and by pouring the extract obtained into an excess of an apolar solvent (e.g. petroleum ether, cyclohexane or pentane3 a precipitate is formed of dihydromocimycin containing less than 5~ of mocimycin.
Highly purified dihydromocimycin can be obtained by passing the product obtained in the way just described over a SEPHADEX (Trade Mark) LH 20 column using the difference in adsorption of mocimycin and dihydromocimycin. The SEPHADEX is suspended in 100% methanol and poured carefully into the column.
After displacement of the methanol with chloroform, the above-mentioned dihydromocimycin precipitate is brought into the column. The eluent used is chloroform. After some time dihydromocimycin is obtained first, followed by mocimycin. Both compounds can be detected in the eluate since they show absorption in the ultra-violet spectrum at 350 nm. The pure compounds may be recovered from the chloroform by precipitation with an apolar solvent such as cyclohexane or pentane.
Confirmation of the identity of the compounds can be obtained by thin layer chromatography. Use is made of Kieselgel F 254 plates, size 20x5 cm (Merck). The eluent is a 60:42:10 mixture of chloroform, ethanol and 25~ ammonia, respectively. Elution time 2 hours. Mocimycin shows an Rf value of 0.3 (main tautomer) and dihydromocimycin shows an Rf value of :`1070630 0.4 (main tautomer).
In an early stage of investigation it was presumed that mocimycin, having a similar anti-microbial spectrum to that of tylosin ~Merck Index, 8th Ed. page 1089), might be effective against Treponema hyodysenteriae causing Treponema dysentery or Vibrio Doyle, one of the most common swine diseases.
Experiments at that time showed that mocimycin was active against this disease, but not more so than tylosin. For that reason no :
further investigations were carried out.
lO As indicated hereinbefore, dihydromocimycin was found to be more active than mocimycin against many microorganisms, and consequently an investigation with this substance was made against the microorganism causing Treponema dysentery. From the experiments it appeared that dihydromocimycin possesses a markedly higher activity against the microorganisms than tylosin and, in addition, was active against tylosin-resistant strains. Thus, dihydromocimycin may be regarded as being superior to tylosin (and also to mocimycin) in the treatment of Treponema dysentery.
According to another feature of the invention there are provided pig feedstuffs supplemented by a significant proportion of dihydromocimycin or a slat, e.g. sodium salt, thereof. The antibiotic or its alkali metal or ammonium or amine salt thereof may also be dispersed in, or mixed with, any suitable inert, physiologically innocuous carrier or diluent, which is orally administrable to a pig, non-reactive with the antibiotic -and not harmful to the pig on oral administration. Effective amounts of dihydromocimycin incorporated in a pig feedstuff for the prevention or treatment of Treponema dysentery are about lO
to about 200 ppm, preferably 20 to 40 ppm, of dihydromocimycin, based on the weight of the feed.
Dihydromocimycin obtained by the procedure hereinbefore described is a fine, easily dusting powder. This could lead to difficulties in the mixing procedure with the feed and, therefore, a premix is preferably made with one or more of the components of the pig feed containing, for example, a 9 to 99-fold amount of the dihydromocimycin. Suitable components for preparing the premix are, for example, corn flour, potato flour and soya flour. Experiments have shown that dihydromocimycin ; has a good stability against pelletising ~granulating under high pressure at high temperatures, using steam).
The premix can be added to the feed as a prophylactic means or as a means for the treatment of pigs only lightly attacked with Treponema dysentery.
When pigs are attacked so heavily with Treponema dysentery that their appetite is lost, or that the sick pigs are pushed away from the feeding trough by healthy pigs, dihydromocimycin is preferably administered through the drinking water, preferably in the presence of a flavouring corrigent.
For that purpose dihydromocimycin is used in a water-soluble form, such as a salt, e.g. a potassium, sodium or amine salt.
Pigs badly attacked with dysentery may be treated by injection of dihydromocimycin or a water-soluble salt thereof, suspended or dissolved in a usual injection liquid, for example, saline, propylene glycol, glycerol-water mixtures, etc.
P,~ Mocimycin shows advantageous growth-promoting properties when fed to live-stock including chickens and other fowl, but dihydromocimycin does not show the aforesaid properties. In addition, therefore, attempts have been made to convert dihydromocimycin into the, for this application, more useful mocimycin.
It has thus been found that dehydrogenation of dihydromocimycin is possible with a special dehydrogenating substance and procedure. Quinones, e.g. 2,3-dicyano-5,6-dichloro-1,4-quinone, p-chloranil and o-chloranil, are not satisfactory ~...
:' -~070630 for the dehydrogenation of dihydromocimycin as other products -~
are formed. Halogenation with cupric bromide, bromine, iodine or N-bromosuccinimide, followed by dehydrohalogenation, did not give the desired result either, even in the presence of catalysts such as benzoyl peroxide and a,~-azo-isobutyronitrile. Attempts to dehydrogenate dihydromocimycin catalytically involve too high temperatures which would lead to decomposition of dihydromocimycin.
Only one dehydrogenation agent, selenium dioxide, has been found to be useful for the dehydrogenation of dihydromocimycin.
Therefore the present invention further relates to a process for the dehydrogenation of dihydromocimycin into mocimycin, which comprises reacting dihydromocimycin with selenium dioxide. This process may advantageously be applied to mixtures of dihydromocimycin and mocimycin as obtained, for example, by the recovery of mocimycin from fermentation liquids in which it is formed.
The dehydrogenation of dihydromocimycin with selenium dioxide may be carried out at ambient temperature, but is preferably carried out at elevated temperatures, e.g. from about 65 to about 110C, preferably from 80 to 95C. The reaction time is from about 10 hours to about 20 minutes in the temperature range of about 65 to about 110C, and is preferably from about 3 hours to about 1 hour in the preferred temperature range. At ambient temperatures the reaction takes about a week.
The reaction is preferably carried out in a solvent medium. Suitable solvents are, for example, hexamethylphosphor-~ triamide (HMPT), dimethyl sulphoxide (DMSO), t-butanol, t-amyl - alcohol, sec-butanol, hexylene glycol, n-butanol, isopropanol, methylcellosolve, dimethylformamide, water, phenylmethylcarbinol and propanol, and mixtures of two or more of those solvents.
Preferred solvents are HMPT, DMSO and t-butanol. The most preferred solvent is HMPT.
:`
-- ~070630 Based on dihydromc)cimycin, a stoichiometric amount or an excess of selenium dioxide is preferred to carry out the dehydrogenation reaction.
Since isolation of both products together from the fermentation liquid is a simple procedure, whereas the separation of dihydromocimycin and mocimycin is much more difficult, the discovery that dihydromocimycin may be converted by chemical means into - for the growth promotion valuable properties -mocimycin, even in a mixture of both compounds, leaving the latter compound substantially unaffected by the process, is very important. Therefore, isolation of the compounds is not necessary for the dehydrogenation of dihydromocimycin in mixtures containing dihydromocimycin and mocimycin.
The invention is illustrated by the following examples.
Preparation of dihydromocimycin The microorganism Streptomyces ramocissimus (CBS 190.69) was fermented in 2,000 litres of a medium containing 20 g of malt paste, 10 g of yeast extract and 5 g of corn steep solids per litre at a pH of about 7 with agitation and aeration. After fermentation the culture medium was mixed with about 2~ of dicalite (an expanded perlite, an aluminium silicate containing potassium, sodium and trace elements) as filter aid, and the mixture was filtered. The filtrate was acidified with 8N
sulphuric acid to pH 6.0 and extracted twice with 1/5th of its volume of methyl isobutyl ketone (MIBK) and emulsions formed were broken with*Hyflo Supercel filter aid (a diatomaceous earth). The organic liquids were mixed and concentrated to about 1 litre by evaporation under reduced pressure and evaporation with a rotary evaporator. From the concentrate formed a crude product was obtained by adding it to 5 times its own volume of petroleum ether (b.p. 40 to 60C) and the precipitate formed *Trade Mark D
1(~7~630 was filtered off with a glass filter (G 3). The precipitate was washed with fresh petroleum ether and dried to obtain a yellow coloured powder containing mocimycin and dihydromocimycin.
A purified form of dihydromocimycin containing not more than 5% of mocimycin was obtained as follows: Gaseous ammonia was passed through the concentrate at a rate of 150 litres per litre of concentrate per hour for 1 minute at a temperature of 2C. A precipitate was formed which contained mocimycin. The precipitate was filtered off and the filtrate was treated once more with gaseous ammonia for 10 to 15 minutes.
The precipitate now formed was filtered off and dissolved in dilute ammonia (pH 9.0). This solution was extracted with an equal volume of methylene chloride and the extract was poured out into 3 to 5 times its own volume of cyclohexane. The precipitate obtained was filtered off, dried and powdered.
The sodium salt of dihydromocimycin was obtained by dissolving dihydromocimycin in water with addition of 0.1N
sodium hydroxide to pH 9 until a saturated solution was obtained.
The solution was filtered and evaporated azeotropically with addition of butanol (in vacuo at about 45C), and the butanolic residue was collected in a small amount of anhydrous butanol.
Petroleum ether was added dropwise to the stirred solution until all the salt was precipitated. The precipitate was filtered off, washed and dried to give the sodium salt of dihydromocimycin. Other salts of dihydromocimycin were prepared in a similar manner.
Preparation of dihydromocimycin in higher yields To obtain a higher yield of dihydromocimycin, a lyophilised culture of Streptomyces ramocissimus (CBS 190.69), or a well sporulated agar culture of the said microorganism, was used for inoculating the contents of a 500 ml erlenmeyer flask containing 100 ml of a sterilised medium of the following ^` 10~0630 composition: 20 g of malt paste, 10 g of yeast extract and 5 g of corn steep solids per litre of tap water, pH 7Ø
After incubation on a rotating shaking device (300 rpm, stroke 2.5 cm) at 30C for three days, the culture obtained was used for inoculating small fermenters containing 2000 ml of the above-mentioned medium to which 20 mg of CoC12.6H20 per litre was added. This growth phase, also effected at 30C, was carried out under conditions of very good aeration in order to stimulate production of dihydromocimycin. For that purpose, more than 2 litres of sterile air were blown through the culture medium per minute, and the culture medium was stirred at a speed up to 1000 rpm. The production of dihydromocimycin started after a fermentation time of about 12 hours and was maximal after about 120 hours. Fermentation on a larger scale was possible by using a 48 hours old culture medium obtained in small fermenters as inoculum for large fermenters.
The dihydromocimycin so produced was recovered from the culture medium as follows: After addition of 2% of diatomaceous earth as a filter aid, the culture was filtered and the filtrate was acidified with 8N sulphuric acid to a pH of 5 to 6 and was extracted twice with 1/5th of its volume of MIBK. If an emulsion formed, it was broken by filtration of the mixture after addition of some diatomaceous earth. The organic layers were collected and concentrated in vacuo to about l/lOth of the original culture volume. Gaseous ammonia was passed through the concentrate at a rate of 150 litres per litre of concentrate per hour for 1 minute. A precipitate was formed which was filtered off. The filtrate was treated once more with gaseous ammonia for 10 to 15 minutes. The precipitate then obtained was dissolved in dilute ammonia (pH 9.0) and purified dihydromocimycin (containing not more than 5% of mocimycin) was obtained by extracting the solution in ammonia with an equal -~ 1070630 volume of methylene chloride. The extract was poured into 3 to 5 times its own volume of cyclohexane and the precipitate obtained was filtered off, dried and powdered.
Dihydromocimycin against Treponema dysentery Twenty pigs, three months old, were infected with the microorganism causing Treponema dysentery by administering to them feed mixed with a homogeneous mixture of contents of the intestines and intestinal mucous membranes of two animals suffering from the disease. The infected pigs were divided up into four groups of five animals each and the animals were fed with the feed as a slurry diluted 1:1 with water for 1 week. The total amount of feed per animal was 1.2 kg each day and was given in two portions.
After S days the first symptoms of the disease were observed from the thin faeces and confirmed by a microbiological investigation of the faeces. After a week the animals were treated as follows:
group 1: no antibiotic was added to the feed;
group 2: 100 ppm of tylosin were added to the feed group 3: 25 ppm of dihydromocimycin were added to the feed~
group 4: 50 ppm of dihydromocimycin were added to the feed.
The antibiotic-enriched feed was administered for a week. After that week feed without any antibiotic was given again. Recovery from the infection was observed from the weights of the animals and from inspection of samples of the faeces, macroscopically from their consistencies, and microscopically by means of a specific immuno-fluorescence technique.
During the test one animal of each groups 1, 3 and 4 died.
The results are shown in the following table, wherein the weights indicated are the averages at that time of the still .
~ - 15 -107()630 living animals. The consistency of the faeces is indicated as follows:
+ means thin liquid; + means thick liquid; - means normal.
The results of the immuno-fluorescence technique are indicated quantitatively by indicating the number of Treponemas in the visual field: 5 means very crowded; 4 means many 3 means about 10 Treponemas; 2 means 1 or 2 Treponemas, 1 means more visual fields necessary to find one Treponema and - means negative.
Group 1 ¦ Group 2 ¦ Group 3 ¦ Group 4 Weights in kg just before infection 24.6 24.4 24.2 23.4 after 1 week (1) 23.7 22.2 21.3 21.6 after 2 weeks 20.9 21.4 20.2 21.2 after 3 weeks 19 8 23.2 24.0 23.0 Faeces consistency - .
after 1 week + + + + + + + + + _ + + + + ~ + + + + +
after 2 weeks + + + + + + + + + + + + + + + + ~ + +
after 3 weeks + + + + ~ + + + + _ _ + + _ _ + _ Immunofluorescence . , ; after 1 week 4 4 4 4 5 4 4 3 4 - 5 4 5 5 ~ 5 - 5 3 3 after 2 weeks 4 4 4 - 4 4 4 2 2 - 4 4 3 1 2 - ~ 4 1 after 3 weeks 2 2 2 2 ~ 3 - - 2 - _ _ - 1 _ _ _ _ (1) at which time the administration of the antibiotics is started;
means: an animal died.
From the faeces consistency as well as from immunofluorescence observations it appeared that the animals treated with dihydromocimycin were cured markedly faster than the animals treated with tylosin. When the administered amounts of antibiotics were also taken into account, it can be concluded ~. ~0~;30 that dihydromocimycin is at least 4 times as active as tylosin.
Dihydromocimycin against Treponema dysentery Pigs, from a farm where problems with pigs scour had existed for some time, were treated under the supervision of the local veterinary surgeon and the inspector of the Health Service Station. The pigs were divided into groups and treated for 4 days in the following manner:
group 1: 66 pigs were treated with feed containing 100 ppm of tylosin;
group 2: 34 pigs were treated with feed containing 25 ppm of dihydromocimycin; '}
group 3: 40 pigs were treated with feed containing 50 ppm of dihydromocimycin;
group 4: 40 pigs were treated with feed containing 100 ppm of dihydromocimycin.
Before the treatment all animals lost thin or very thin faeces. Samples thereof were investigated and found to be Treponema-positive, and Salmonella-negative. Sometimes worm eggs were found.
One day after the start of the treatment the faeces of the pigs of group 4 were normal. The animals of group 1 were cured only after 3 to 4 days. The animals of groups 2 and 3 were cured in periods lying between those of groups 1 and 4.
The animals treated with dihydromocimycin appeared to be much more liverly than before the treatment. The animals were not averse to feed containing dihydromocimycin and the general conclusion was that a dosage of 25 ppm of dihydromocimycin was better than a dosage of 100 ppm of tylosin in the curing of Treponema dysentery.
"` 1070630 Dehydrogenation of dihydromocimycin A solution was made of 1 g of dihydromocimycin in 15 ml of HMPT (technical grade, dried over a molecular sieve 3A) and an amount of 139 mg (1.25 mmoles) of selenium dioxide was added.
The mixture was heated on a steam bath for 100 minutes and an additional amount of 139 mg of selenium dioxide was added after 60 minutes. The selenium formed after cooling was separated by filtration through a G4 glass filter and the precipitate was washed with a small amount of methanol. The filtrate was poured into 350 ml of distilled water and the precipitate formed was filtered off and washed with distilled water. The filtrate was stored.
; The precipitate was dissolved in methanol and diluted with MIBK. The solution was evaporated at 40C under reduced pressure until methanol and water were removed. A precipitate was formed which did not contain mocimycin as indicated by a thin-layer chromatographed (TLC) test and it consisted of polar impurities only. The precipitate was filtered off and washed with MIBK. The filtrate was added dropwise to an excess of petroleum ether (b.p. 40 to 60C) and the precipitate formed was filtered off, washed with petroleum ether and dried to obtain 500 mg of product.
The stored filtrate was extracted with MIBK, and the extract was added dropwise to petroleum ether to obtain another 100 mg of product of the same quality so that the total yield was 650 g. A thin layer chromatographic test showed that the final product contained mocimycin with only a trace of dihydromocimycin.
Dehydrogenation of dihydromocim~cin .
This experiment was carried out in duplicate. 2.4 g 1~70630 of a composition containing 22.8% of mocimycin and 35.5% of dihydromocimycin was dissolved in 50 ml of HMPT. An amount of 350 mg of selenium dioxide was added and the mixture was kept at 105C for 45 minutes with stirring. According to a thin layer chromatographic test dihydromocimycin was not present anymore.
The mixture was cooled to room temperature and filtered through a glass filter G 4, removing the black selenium formed and a small amount of unreacted selenium dioxide.
The precipitate was washed with MIBK and to the combined filtrate and MIBK washings 350 ml of water, 10 g of sodium chloride and 5 ml of 4 N hydrogen chloride were added.
This mixture was extracted 3 times with 100 ml of MIBK each.
The combined MIBK extracts were washed with 100 ml of water and the water layer was removed. The MIBK phase was dried over anhydrous magnesium sulphate which eventually was washed with a little MIBK. The MIBK phase was then evaporated in vacuo at a temperature of about 20C until 25 ml were left. The residue was added dropwise to 500 ml of stirred petroleum ether (40 - 60C) and the precipitate formed was filtered off, washed with petroleum ether (40 - 60C) and dried in a vacuum drying oven at room temperature during the night.
In the first experiment the following yield was obtained: 1.64 g of a product containing 41.2% of mocimycin and ~ 2% of dihydromocimycin (as determined by high pressure liquid chromatography).
In the second experiment the yield was 1.79 g of a product containing 41.6% of mocimycin and _ 1% of dihydromocimycin.
Dehydrogenation of dihydromocimycin, influence of solvents In this example several solvents were tested to find ; out which one is preferred for the dehydrogenation of dihydromoci-mycin. In all experiments 50 mg of a technical preparation .. -- 19 --.:
, . . . . . .
containing dihydromocimycin and mocimycin were reacted with 20 mg (0.18 mmole) of selenium dioxide in 3 ml of solvent at a temperature of 80C. At 2, 4 and 7 hours after the start a sample was taken for a thin-layer chromatographic test (if necessary after sample preparation) on a "Kieselgel" 60 disc (Merck) using a 50:45:5 mixture of MIBK, acetone and water as the eluent. Detection was carried out by carbonization after spraying with a sulphuric acid-diethyl ether mixture. A
qualitative picture of the reaction was obtained in this manner.
The results are as follows: Decomposition or no reaction was obtained in propargyl alcohol, diacetone alcohol, nitromethane, propylene carbonate, acetonitrile, pyridine, sulpholane, benzylalcohol, mesityl oxide, ethylene carbonate, N-methyl-2-pyrrolidone, N,N-dimethylacetamide, dioxan, MIBK, butyl acetate, amyl acetate, N-methylacetamide, anisole, diglyme and 1,2-dichloroethane. A poor conversion was obtained in tetramethylurea, a 0.1 M buffer of NaHCO3/Na2CO3 of pH 9.1, n-propanol, phenylmethylcarbinol, water, and dimethylformamide.
A somewhat better conversion was obtained in methylcellosolve, isopropanol, n-butanol, hexylene glycol, sec-butanol and t-amyl alcohol. A moderate conversion was obtained in t-butanol, and dimethyl sulphoxide. The best result was obtained in HMPT.
Dehydrogenation of dihydromocimycin in mixtures of solvents In this Example mixtures of solvents with HMPT as one of the components were tested to find out the preferred mixture for carrying out the dehydrogenation of dihydromocimycin.
In each of the experiments 2.4 g of the preparation as used as the starting material in Example 7 were used. After the reaction (i.e. after all dihydromocimycin was converted according to a TLC test), the reaction mixtures were recovered as follows:
..
1~7C~630 After cooling the reaction mixture was filtered through a G4 glass filter to remove the selenium formed and the filter was washed with a small amount of methanol. The filtrate was poured into an excess of water and was acidified to pH 3 and then extracted three times with 1/4th of its volume of MIBK. A tarry interlayer which was formed was extracted with MIBK again by dissolving it in methanol first and diluting it with MIBK and water thereafter. The combined MIBK extracts were washed three times with l/3rd of its volume of water, and the organic layer was concentrated in vacuo at about 40C. In all cases a precipitate was formed essentially consisting of decomposition products (according to TLC). The.precipitate was filtered and washed with MIBK and the combined MIBK
concentrates were added slowly, with stirring, to an excess of petroleum ether (b.p. 40 to 60C). The precipitate formed was filtered, washed with petroleum ether and dried.. The results of the experiments are shown in the following table:
.
-- 107()630 Amount of Reaction Overall SeO2- Yield Moles solvent temperature reaction addltion (% by SeO2 (C) time in grams weight) added (hrs) and time per of mole of addition mixture after start of reaction HMPT 25 ml 90 2 0.5 start 423:1 H2O 35 ml + 0.5 after 55 min . I .
HMPT 15 ml 90 2 3/4 0.1 start 501.2:1 0.1 M 0.1 after NaHCO3- 20 min Na CO 0.1 after bu~fe~ pH 85 min 9.1 25 ml 0.1 after 130 min .
t-BuOH 84 3 0.1 start 421.5:1 20 ml 0.1 after HMPT 10 ml 25 min 45 min 0.1 after 75 min 0.1 after 120 min ~ 30 t-AmOH 96 0.3S start 71 3.2:1 : 100 ml 0.35 afte HMPT 50 ml 70 min :
: 0.35 after . 110 min I ~
t-AmOH 96 3 0.35 start 55 3.2:1 150 ml 0.35 after 75 min :~:
0.35 after .
. 150 min ; .
t-BuOH 80 2 1.0 start 426:1 100 ml 1.0 after HMPT 50 ml 35 min HMPT 95reaction 0.4 start 791.2:1 150 ml stopped after 1 hr .. . . . .
.
1~70630 The following abbrevations are used:
HMPT = hexamethylphosphortriamide t-BuOH = t-butanol t-AmOH = t-amyl alcohol The table shows that the highest yield (79~) is obtained when pure HMPT is used as the solvent. A high yield is also obtained in a mixture of HMPT and t-amyl alcohol.
' ... .
.
: ` : . .
Claims (12)
1. A process for the preparation of dihydromocimycin having the structural formula:
or a non-toxic, pharmaceutically-acceptable salt thereof, which comprises the steps of aerobically cultivating the microorganism Streptomyces ramocissimus (CBS 190.69) or a dihydromocimycin-producing mutant thereof in an aqueous nutrient medium containing assimilable sources of carbon, nitrogen and inorganic substances, and separating the dihydromocimycin formed during cultivation, and, if desired, converting said dihydromocimycin into a non-toxic pharmaceutically-acceptable salt thereof.
or a non-toxic, pharmaceutically-acceptable salt thereof, which comprises the steps of aerobically cultivating the microorganism Streptomyces ramocissimus (CBS 190.69) or a dihydromocimycin-producing mutant thereof in an aqueous nutrient medium containing assimilable sources of carbon, nitrogen and inorganic substances, and separating the dihydromocimycin formed during cultivation, and, if desired, converting said dihydromocimycin into a non-toxic pharmaceutically-acceptable salt thereof.
2. The process of claim 1 wherein the salt obtained is an alkali metal salt, an ammonium salt or an amine salt.
3. The process of claim 1, wherein aeration rates are applied of 1 to 3 litres of air per 2 litres of culture medium per minute.
4. The process of claim 1, wherein aeration rates are applied of 1.5 to 2.5 litres of air per 2 litres of culture medium per minute.
5. The process of claim 1, wherein low concentrations of iron, cobalt or nickel ions are present in the culture medium.
6. The process of claim 1, wherein the separation of dihydromocimycin from mocimycin is carried out by means of an alkaline compound such as ammonia, sodium methoxide or triethyl-amine.
7. The compound dihydromocimycin having the structural formula or a non-toxic, pharmaceutically-acceptable salt thereof, whenever prepared according to the process of claim 1.
8. An alkali metal salt, an ammonium salt or an amine salt of dihydromocimycin, whenever prepared according to the process of claim 2.
9. The compound dihydromocimycin or a non-toxic pharmaceutically-acceptable salt thereof, whenever prepared according to the process of claim 3.
10. The compound dihydromocimycin or a non-toxic pharmaceutically-acceptable salt thereof, whenever prepared according to the process of claim 4.
11. The compound dihydromocimycin or a non-toxic pharmaceutically-acceptable salt thereof, whenever prepared according to the process of claim 5.
12. The compound dihydromocimycin or a non-toxic pharmaceutically-acceptable salt thereof, whenever prepared according to the process of claim 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA324,111A CA1074307A (en) | 1975-05-16 | 1979-03-26 | Antibiotic |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB20926/75A GB1545474A (en) | 1975-05-16 | 1975-05-16 | Mocimycin derivatives |
| GB3064675 | 1975-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1070630A true CA1070630A (en) | 1980-01-29 |
Family
ID=26254986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA252,534A Expired CA1070630A (en) | 1975-05-16 | 1976-05-14 | Dihydromocimycin from streptomyces ramocissimus |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JPS52277A (en) |
| AU (1) | AU499529B2 (en) |
| CA (1) | CA1070630A (en) |
| CH (1) | CH630411A5 (en) |
| DE (1) | DE2658977C3 (en) |
| DK (1) | DK143606C (en) |
| FI (1) | FI54308C (en) |
| FR (1) | FR2310760A1 (en) |
| IE (1) | IE43106B1 (en) |
| IT (1) | IT1070097B (en) |
| LU (1) | LU74958A1 (en) |
| NL (1) | NL162136C (en) |
| NZ (1) | NZ180860A (en) |
| SE (2) | SE435512B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55142039A (en) * | 1979-04-23 | 1980-11-06 | Tokuyama Soda Co Ltd | Polypropylene composition |
| JPS621988A (en) * | 1985-06-27 | 1987-01-07 | 積水化学工業株式会社 | Window frame |
| JPS621987A (en) * | 1985-06-27 | 1987-01-07 | 積水化学工業株式会社 | Window frame |
| JPH0815434B2 (en) * | 1987-02-03 | 1996-02-21 | 三菱化学株式会社 | Novel antibiotic vermisporin and method for producing the same |
| JPH02128783U (en) * | 1989-03-31 | 1990-10-24 |
-
1976
- 1976-05-13 IE IE1021/76A patent/IE43106B1/en unknown
- 1976-05-13 NZ NZ180860A patent/NZ180860A/en unknown
- 1976-05-13 DK DK215176A patent/DK143606C/en not_active IP Right Cessation
- 1976-05-13 NL NL7605093.A patent/NL162136C/en not_active IP Right Cessation
- 1976-05-13 AU AU13930/76A patent/AU499529B2/en not_active Expired
- 1976-05-14 SE SE7605536A patent/SE435512B/en not_active IP Right Cessation
- 1976-05-14 CH CH610676A patent/CH630411A5/en not_active IP Right Cessation
- 1976-05-14 JP JP51055985A patent/JPS52277A/en active Granted
- 1976-05-14 CA CA252,534A patent/CA1070630A/en not_active Expired
- 1976-05-14 FI FI761380A patent/FI54308C/en not_active IP Right Cessation
- 1976-05-14 LU LU74958A patent/LU74958A1/xx unknown
- 1976-05-14 FR FR7614694A patent/FR2310760A1/en active Granted
- 1976-05-14 DE DE2658977A patent/DE2658977C3/en not_active Expired
- 1976-05-14 IT IT68189/76A patent/IT1070097B/en active
-
1980
- 1980-08-07 SE SE8005599A patent/SE8005599L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE2658977C3 (en) | 1978-09-28 |
| DK143606B (en) | 1981-09-14 |
| JPS5522479B2 (en) | 1980-06-17 |
| NL7605093A (en) | 1976-11-18 |
| DE2658977B2 (en) | 1978-01-26 |
| DE2658977A1 (en) | 1977-05-05 |
| DE2621615A1 (en) | 1976-11-25 |
| CH630411A5 (en) | 1982-06-15 |
| FI761380A (en) | 1976-11-17 |
| NL162136B (en) | 1979-11-15 |
| DK143606C (en) | 1982-02-22 |
| IE43106B1 (en) | 1980-12-17 |
| NL162136C (en) | 1980-04-15 |
| FR2310760B1 (en) | 1978-11-17 |
| FI54308C (en) | 1978-11-10 |
| LU74958A1 (en) | 1977-01-17 |
| NZ180860A (en) | 1978-04-03 |
| IT1070097B (en) | 1985-03-25 |
| DK215176A (en) | 1976-11-17 |
| DE2621615B2 (en) | 1977-07-07 |
| AU499529B2 (en) | 1979-04-26 |
| SE435512B (en) | 1984-10-01 |
| IE43106L (en) | 1976-11-16 |
| FI54308B (en) | 1978-07-31 |
| FR2310760A1 (en) | 1976-12-10 |
| SE8005599L (en) | 1980-08-07 |
| JPS52277A (en) | 1977-01-05 |
| SE7605536L (en) | 1976-11-17 |
| AU1393076A (en) | 1977-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2517316A1 (en) | CLAVULANIC ACID, THEIR SALTS AND ESTERS, PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
| US3616242A (en) | Hydrolysis process for the preparation of rubidomycin | |
| CA1070630A (en) | Dihydromocimycin from streptomyces ramocissimus | |
| US4062948A (en) | Dihydromocimycin antibiotics | |
| US4129578A (en) | Polycyclic ether antibiotic | |
| US2773878A (en) | Cycloserine and production thereof | |
| CA1074307A (en) | Antibiotic | |
| Egawa et al. | ANTIBIOTIC YC 73 OF PSEUDOMONAS ORIGIN. I PRODUCTION, ISOLATION AND PROPERTIES | |
| US4478831A (en) | Antibiotics, pharmaceutical compositions and method of use | |
| US3927211A (en) | Antibiotic MYC 8003 and process for producing same | |
| US4226879A (en) | Antibiotic composition | |
| US3923981A (en) | Antibiotic MYC 8003 | |
| US3987028A (en) | Antibiotic 20,798 r.p. | |
| US4031206A (en) | Antibiotics produced by species of pseudonocardia | |
| JPS6261037B2 (en) | ||
| US4264591A (en) | Antibiotic, its production and its medicinal use | |
| US2895952A (en) | Purification of novobiocin | |
| CA1054082A (en) | Antibiotic | |
| US4065356A (en) | Production of antibiotic FR-02A (efrotomycin) by streptomyces lactamdurans | |
| US3991183A (en) | Antibiotic produced by a species of micromonospora | |
| US4232006A (en) | Antibiotic W-10 complex, antibiotic 20561 and antibiotic 20562 as antifungal agents | |
| US4137224A (en) | Process for the preparation of antibiotic W-10 complex and for the isolation of antibiotic 20561 and antibiotic 20562 therefrom | |
| US4331658A (en) | Method of treating swine dysentery with antibiotic A-32887 | |
| US4230799A (en) | Process for the preparation of antibiotic W-10 complex and for the isolation of Antibiotic 20561 and Antibiotic 20562 therefrom | |
| US4054564A (en) | 7-(5-Amino-5-carboxyvaleramido)-7-methoxycephalosporanic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |